(Q35028375)

5 August 2017

1 reference

title

The second generation of COX-2 inhibitors: what advantages do the newest offer? (English)

1 reference

5 August 2017

Dirk O Stichtenoth

1

1 reference

PubMed ID

12487621

5 August 2017

Jürgen C Frölich

series ordinal

2

1 reference

5 August 2017

1 January 2003

1 reference

5 August 2017

1 reference

5 August 2017

63

1 reference

5 August 2017

33-45

1 reference

5 August 2017

1

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200363010-00003

5 August 2017

0 references

cites work

Therapy with preferential and specific COX-2 inhibitors

1 reference

12 December 2020

Valdecoxib, a cyclooxygenase-2-specific inhibitor, is effective in treating primary dysmenorrhea

1 reference

12 December 2020

Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor

1 reference

12 December 2020

TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue

1 reference

12 December 2020

Upper GI mucosal effects of parecoxib sodium in healthy elderly subjects

1 reference

12 December 2020

The influence of parecoxib, a parenteral cyclooxygenase-2 specific inhibitor, on the pharmacokinetics and clinical effects of midazolam

1 reference

12 December 2020

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2

1 reference

12 December 2020

Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis

1 reference

12 December 2020

Efficacy and safety of intravenous parecoxib sodium in relieving acute postoperative pain following gynecologic laparotomy surgery

1 reference

12 December 2020

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

1 reference

12 December 2020

Nomenclature for COX-2 inhibitors.

1 reference

12 December 2020

N-[[(5-methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX-2 for parenteral administration

1 reference

12 December 2020

A single preoperative oral dose of valdecoxib, a new cyclooxygenase-2 specific inhibitor, relieves post-oral surgery or bunionectomy pain

1 reference

12 December 2020

Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis

1 reference

12 December 2020

Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.

1 reference

12 December 2020

Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen

1 reference

12 December 2020

The classification of cyclooxygenase inhibitors

1 reference

12 December 2020

A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis.

1 reference

12 December 2020

Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib).

1 reference

12 December 2020

Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib

1 reference

12 December 2020

Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial

1 reference

12 December 2020

A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin

1 reference

12 December 2020

Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis

1 reference

12 December 2020

NSAIDs: time to re-evaluate gut toxicity

1 reference

12 December 2020

Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor

1 reference

12 December 2020

Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment

1 reference

12 December 2020

Cyclooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors

1 reference

12 December 2020

COX-2 and the kidneys

1 reference

12 December 2020

Effects of parecoxib, a parenteral COX-2-specific inhibitor, on the pharmacokinetics and pharmacodynamics of propofol

1 reference

12 December 2020

4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2

1 reference

12 December 2020

Parecoxib (parecoxib sodium).

1 reference

12 December 2020

Basic biology and clinical application of specific cyclooxygenase-2 inhibitors

1 reference

12 December 2020

Intravenous parecoxib sodium foracute pain after orthopedic knee surgery.

1 reference

12 December 2020

Valdecoxib, a COX-2-specific inhibitor, is an efficacious, opioid-sparing analgesic in patients undergoing hip arthroplasty

1 reference

12 December 2020

Valdecoxib is more efficacious than rofecoxib in relieving pain associated with oral surgery

1 reference

12 December 2020

In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663).

1 reference

12 December 2020

1 reference

12 December 2020

Risk of cardiovascular events associated with selective COX-2 inhibitors

1 reference

12 December 2020

Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen

1 reference

12 December 2020

Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis.

1 reference

12 December 2020

Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee

1 reference

12 December 2020

Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids

1 reference

12 December 2020

Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs

1 reference

12 December 2020

Towards a better aspirin

1 reference

12 December 2020

Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in healthy volunteers

1 reference

12 December 2020

A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes

1 reference

12 December 2020

Anesthesiology. Second of two parts

1 reference

12 December 2020

Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing

1 reference

12 December 2020

The coxibs, selective inhibitors of cyclooxygenase-2.

1 reference

12 December 2020

1 reference

12 December 2020

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

12 December 2020

Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice

1 reference

12 December 2020

The analgesic efficacy of valdecoxib vs. oxycodone/acetaminophen after oral surgery

1 reference

12 December 2020

10.2165/00003495-200363010-00003

Identifiers

DOI

1 reference

PubMed ID

12487621

Dimensions Publication ID

5 August 2017

0 references

1 reference

PubMed ID

12487621